GeNeuro, Servier deal

Servier exercised its option under a 2014 deal and will become a minority shareholder in GeNeuro. The exercise follows the start of a Phase IIb trial evaluating GNbAC1 to treat relapsing-remitting multiple sclerosis (RRMS). Servier has the option to license exclusive rights to develop and commercialize GNbAC1 worldwide, excluding the U.S. and Japan, once the trial is completed. Servier is also paying GeNeuro EUR37.5 million ($41 million) to complete the trial. ...